相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
Mazyar Shadman et al.
BLOOD (2022)
A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL
Kohta Miyawaki et al.
BLOOD ADVANCES (2022)
Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
Mika Casey et al.
Blood Advances (2022)
Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models
Haohai Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function
Yasuhiro Nagate et al.
LEUKEMIA (2021)
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2021)
Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis
Capucine L. Grandjean et al.
SCIENCE ADVANCES (2021)
ATP and cancer immunosurveillance
Oliver Kepp et al.
EMBO JOURNAL (2021)
Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis
Roarke A. Kamber et al.
NATURE (2021)
The P2X7 Receptor in Tumor Immunity
Fabio Grassi et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
Benoit Manfroi et al.
BLOOD ADVANCES (2021)
The Cancer-Immunity Cycle in Multiple Myeloma
Mika Casey et al.
IMMUNOTARGETS AND THERAPY (2021)
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Chunxiao Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Kyohei Nakamura et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
On the mechanism of anti-CD39 immune checkpoint therapy
David Allard et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Combination of CD47 and signal-regulatory protein-α constituting the don't eat me signal is a prognostic factor in diffuse large B-cell lymphoma
Ryo Kazama et al.
CANCER SCIENCE (2020)
Targeting an adenosine-mediated don't eat me signal augments anti-lymphoma immunity by anti-CD20 monoclonal antibody
Kyohei Nakamura et al.
LEUKEMIA (2020)
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
Rui Yang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cancer immunoediting and immune dysregulation in multiple myeloma
Kyohei Nakamura et al.
BLOOD (2020)
The adenosine pathway in immuno-oncology
Bertrand Allard et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino et al.
BLOOD ADVANCES (2020)
Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism
Bradley N. Spatola et al.
MABS (2020)
Intercellular Calcium Signaling Induced by ATP Potentiates Macrophage Phagocytosis
Sara Zumerle et al.
CELL REPORTS (2019)
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
Ivan Perrot et al.
CELL REPORTS (2019)
EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2
Alexandre S. Cristino et al.
BLOOD (2019)
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng et al.
NATURE REVIEWS CANCER (2019)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Amira A. Barkal et al.
NATURE IMMUNOLOGY (2018)
Endotoxin-induced autocrine ATP signaling inhibits neutrophil chemotaxis through enhancing myosin light chain phosphorylation
Xu Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
TAMeless traitors: macrophages in cancer progression and metastasis
Shweta Aras et al.
BRITISH JOURNAL OF CANCER (2017)
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
Colm Keane et al.
LANCET HAEMATOLOGY (2015)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Sari Riihijarvi et al.
HAEMATOLOGICA (2015)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W. Scott et al.
BLOOD (2014)
TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses
Heather B. Cohen et al.
BLOOD (2013)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV
Veronique Minard-Colin et al.
BLOOD (2008)